Janssen launches global health unit

Share this article:

Johnson & Johnson's Janssen division has launched a global public health group. Janssen said in its Thursday announcement that the new division will unify Janssen's “commitment to research, develop and deliver transformational medicines to address the world's greatest unmet public health needs.”

Paul Stoffels, who is chief scientific officer of J&J and worldwide chairman of Janssen, said in a statement that the new unit gives the company "a more focused approach to further develop and introduce our most promising medicines."

The unit is also charged with increasing medication access and will build on and incorporate practices from Janssen's global access and partnerships program, which is focused on increasing access to HIV medications.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.